Barclays raised the firm’s price target on 10x Genomics to $55 from $45 and keeps an Overweight rating on the shares. The analyst downgraded the U.S. life science tools and diagnostics industry to Neutral from Positive on valuation along with two stocks, Danaher (DHR) and Thermo Fisher Scientific (TMO). Given recent run in shares, stocks trade at or above historical premiums to the market, leaving little room for more multiple expansion, the analyst tells investors in a research note. The firm struggles to see significant earnings upside to current estimates due to macro uncertainty across the end markets. Investors already pulling forward 2025 numbers to justify valuations, “which sets the space up for downside if recoveries take longer than expected,” contends Barclays.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TXG:
- 10x Genomics’s preliminary Q4 results ahead of Street estimates, says Canaccord
- 10x Genomics sees FY23 revenue approximately $618.7M, consensus $614.69M
- 10x Genomics Announces Preliminary Fourth Quarter and Full Year 2023 Results
- 10x Genomics sees Q4 revenue approximately $184M, consensus $179M
- 10x Genomics’ three platforms featured in published study on breast tumors